These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2651758)

  • 1. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial.
    Baker LR; Abrams L; Roe CJ; Faugere MC; Fanti P; Subayti Y; Malluche HH
    Kidney Int; 1989 Feb; 35(2):661-9. PubMed ID: 2651758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early therapy of renal bone disease with calcitriol: a prospective double-blind study.
    Baker LR; Abrams SM; Roe CJ; Faugere MC; Fanti P; Subayti Y; Malluche HH
    Kidney Int Suppl; 1989 Nov; 27():S140-2. PubMed ID: 2699994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results.
    Coen G; Mazzaferro S; Bonucci E; Ballanti P; Massimetti C; Donato G; Landi A; Smacchi A; Della Rocca C; Cinotti GA
    Miner Electrolyte Metab; 1986; 12(5-6):375-82. PubMed ID: 3492662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
    Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
    Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up.
    Coen G; Mazzaferro S; Bonucci E; Taggi F; Ballanti P; Bianchi AR; Donato G; Massimetti C; Smacchi A; Cinotti GA
    Kidney Int; 1985 Nov; 28(5):783-90. PubMed ID: 3878905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E; Bondatti F; Manni M; Pasquali M; Perruzza I; Sardella D; Spurio A
    Am J Nephrol; 1992; 12(4):246-51. PubMed ID: 1481872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic effect of 1,24(R)(OH)2D3 versus 1,25(OH)2D3 administration in chronic renal failure.
    Coen G; Bondatti F; Donato G; Mazzaferro S; Pasquali M; Rosini S; Sardella D; Taggi F
    J Steroid Biochem Mol Biol; 1992 Sep; 42(8):823-9. PubMed ID: 1525043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is 1,25-dihydroxy-cholecalciferol harmful to renal function in patients with chronic renal failure?
    Christiansen C; Rødbro P; Christensen MS; Hartnack B
    Clin Endocrinol (Oxf); 1981 Sep; 15(3):229-36. PubMed ID: 6273027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25(OH)2D3 and renal function. A controlled clinical study in normal elderly women.
    Jensen GF; Christiansen C; Transbøl I
    Acta Med Scand; 1982; 211(1-2):51-4. PubMed ID: 7041522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of secondary hyperparathyroidisms of predialysis chronic renal failure with low doses of 1.25(OH)2D3].
    Kato N; Kasai K; Kawaguchi Y; Yamamoto H; Shigematu T; Sakai O
    Nihon Jinzo Gakkai Shi; 1995 Oct; 37(10):543-8. PubMed ID: 7474506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term low-dose calcitriol treatment in predialysis chronic renal failure: can it prevent hyperparathyroid bone disease?
    Nordal KP; Dahl E; Halse J; Attramadal A; Flatmark A
    Nephrol Dial Transplant; 1995; 10(2):203-6. PubMed ID: 7753453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
    Perez-Mijares R; Gomez-Fernandez P; Almaraz-Jimenez M; Ramos-Diaz M; Rivero-Bohorquez J
    Am J Nephrol; 1993; 13(2):149-54. PubMed ID: 8342582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis.
    Caniggia A; Delling G; Nuti R; Lorè F; Vattimo A
    Acta Vitaminol Enzymol; 1984; 6(2):117-28. PubMed ID: 6388277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic renal failure and vitamin D metabolites: a status report.
    Christiansen C
    J Steroid Biochem; 1983 Jul; 19(1B):517-23. PubMed ID: 6310241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.